These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 8847480

  • 1. Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action.
    Haubenwallner S, Essenburg AD, Barnett BC, Pape ME, DeMattos RB, Krause BR, Minton LL, Auerbach BJ, Newton RS, Leff T.
    J Lipid Res; 1995 Dec; 36(12):2541-51. PubMed ID: 8847480
    [Abstract] [Full Text] [Related]

  • 2. Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia.
    Kłosiewicz-Latoszek L, Szostak WB.
    Eur J Clin Pharmacol; 1991 Dec; 40(1):33-41. PubMed ID: 2060543
    [Abstract] [Full Text] [Related]

  • 3. A novel compound that elevates high density lipoprotein and activates the peroxisome proliferator activated receptor.
    Bisgaier CL, Essenburg AD, Barnett BC, Auerbach BJ, Haubenwallner S, Leff T, White AD, Creger P, Pape ME, Rea TJ, Newton RS.
    J Lipid Res; 1998 Jan; 39(1):17-30. PubMed ID: 9469582
    [Abstract] [Full Text] [Related]

  • 4. Fibrates and triglyceride metabolism.
    Schwandt P.
    Eur J Clin Pharmacol; 1991 Jan; 40 Suppl 1():S41-3. PubMed ID: 2044642
    [Abstract] [Full Text] [Related]

  • 5. Developmental and pharmacological regulation of apolipoprotein C-II gene expression. Comparison with apo C-I and apo C-III gene regulation.
    Andersson Y, Majd Z, Lefebvre AM, Martin G, Sechkin AV, Kosykh V, Fruchart JC, Najib J, Staels B.
    Arterioscler Thromb Vasc Biol; 1999 Jan; 19(1):115-21. PubMed ID: 9888873
    [Abstract] [Full Text] [Related]

  • 6. Peroxisome proliferator-activated receptor alpha is not rate-limiting for the lipoprotein-lowering action of fish oil.
    Dallongeville J, Baugé E, Tailleux A, Peters JM, Gonzalez FJ, Fruchart JC, Staels B.
    J Biol Chem; 2001 Feb 16; 276(7):4634-9. PubMed ID: 11050100
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha.
    Kockx M, Gervois PP, Poulain P, Derudas B, Peters JM, Gonzalez FJ, Princen HM, Kooistra T, Staels B.
    Blood; 1999 May 01; 93(9):2991-8. PubMed ID: 10216095
    [Abstract] [Full Text] [Related]

  • 11. Opposite effects of bezafibrate and gemfibrozil in both normal and hypertriglyceridemic rats.
    Krause BR, Barnett BC, Essenburg AD, Kieft KA, Auerbach BJ, Bousley R, Stanfield R, Newton RS, Bisgaier CL.
    Atherosclerosis; 1996 Nov 15; 127(1):91-101. PubMed ID: 9006809
    [Abstract] [Full Text] [Related]

  • 12. Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse.
    Chianale J, Vollrath V, Wielandt AM, Amigo L, Rigotti A, Nervi F, Gonzalez S, Andrade L, Pizarro M, Accatino L.
    Biochem J; 1996 Mar 15; 314 ( Pt 3)(Pt 3):781-6. PubMed ID: 8615769
    [Abstract] [Full Text] [Related]

  • 13. Decreased susceptibility to copper-induced oxidation of rat-lipoproteins after fibrate treatment: influence of fatty acid composition.
    Vázquez M, Merlos M, Adzet T, Laguna JC.
    Br J Pharmacol; 1996 Mar 15; 117(6):1155-62. PubMed ID: 8882610
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Relationship between plasma lipids and palmitoyl-CoA hydrolase and synthetase activities with peroxisomal proliferation in rats treated with fibrates.
    Alegret M, Ferrando R, Vázquez M, Adzet T, Merlos M, Laguna JC.
    Br J Pharmacol; 1994 Jun 15; 112(2):551-6. PubMed ID: 7915611
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome.
    Chan DC, Watts GF, Ooi EM, Ji J, Johnson AG, Barrett PH.
    Arterioscler Thromb Vasc Biol; 2008 Oct 15; 28(10):1831-7. PubMed ID: 18566295
    [Abstract] [Full Text] [Related]

  • 18. Fibrate treatment does not modify the expression of acyl coenzyme A oxidase in human liver.
    Roglans N, Bellido A, Rodríguez C, Cabrero A, Novell F, Ros E, Zambón D, Laguna JC.
    Clin Pharmacol Ther; 2002 Dec 15; 72(6):692-701. PubMed ID: 12496750
    [Abstract] [Full Text] [Related]

  • 19. Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil).
    Farnier M, Salko T, Isaacsohn JL, Troendle AJ, Dejager S, Gonasun L.
    Am J Cardiol; 2003 Oct 01; 92(7):794-7. PubMed ID: 14516878
    [Abstract] [Full Text] [Related]

  • 20. No effect of fibrates on synthesis of apolipoprotein(a) in primary cultures of cynomolgus monkey and human hepatocytes: apolipoprotein A-I synthesis increased.
    Neele DM, Kaptein A, Huisman H, de Wit EC, Princen HM.
    Biochem Biophys Res Commun; 1998 Mar 17; 244(2):374-8. PubMed ID: 9514936
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.